Brian O Mahony/X
Sep 13, 2025, 13:34
Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
Brian O Mahony, CEO of Irish Haemophilia Society, Former President of WFH and EHC, shared a post on X:
“Nugent BIC2025 presents 5 year data on valoctocogene roxaparvovec (Roctavian) GENE R-8 1 trial.
128 of 134 participants completed the trial. Using chromogenic assay at 5 years, mean FVIII 13.7, median 6.2 IU/dl 1/3”
Stay informed with Hemostasis Today.
-
Feb 16, 2026, 12:55Hussein Balfaqih: From Near‑Fatal Hemorrhage to Walking The Ward
-
Feb 16, 2026, 06:21C. Michael Gibson: Favorable Safety Outcomes With Asundexian
-
Feb 16, 2026, 06:18Jecko Thachil: What Do Clinicians Mean by “Coagulopathy”?
-
Feb 16, 2026, 06:04Inside 2026 Highlights of ASH in the Mediterranean, Middle East, and North Africa with Dr. Heghine Khachatryan
-
Feb 15, 2026, 10:56Don’t Miss PNH: Clinical Practice From ISTH – Medscape
-
Feb 15, 2026, 10:52Awareness and Research on Factor V Deficiency Are Critical – EHC
-
Feb 15, 2026, 10:43Peter Zdziarski: Protecting Patient Data in the Rare Disease Community
-
Feb 15, 2026, 10:31Michiel Voet: The Price Tag of a Whole Blood Strategy
-
Feb 15, 2026, 10:26Sifat Jubaira: K₂-EDTA vs K₃-EDTA – Same Anticoagulant, Very Different Accuracy